Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma and Leukemia（2023）
关键词
relapsed/refractory multiple myeloma,multiple myeloma,bortezomib,mezigdomide,mezigdomide
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要